Experimental Hematology
Volume 37, Issue 7 , Pages 831-837 , July 2009

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line

  • Shuqing Lü

      Affiliations

    • Department of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China
    • ,
  • Jianmin Yang

      Affiliations

    • Department of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China
    • ,
  • Zhilong Chen

      Affiliations

    • Department of Pharmaceutical Science and Technology, Institute of Biological Science and Technology, Donghua University, Shanghai, China
    • ,
  • Shenglan Gong

      Affiliations

    • Department of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China
    • ,
  • Hong Zhou

      Affiliations

    • Department of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China
    • ,
  • Xiaoqian Xu

      Affiliations

    • Department of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China
    • ,
  • Jianmin Wang

      Affiliations

    • Department of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China
    • Corresponding Author InformationOffprint requests to: Jianmin Wang, M.D., Department of Hematology, Changhai Hospital, Second Military Medical University, 174 Changhai Road, Shanghai, 200433, P.R. China

Received 4 January 2009 ,Revised 16 March 2009 ,Accepted 6 April 2009.

References 

  1. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Ann Rev Biochem. 1999;68:1015–1068
  2. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23:630–639
  3. Daniel KG, Kuhn DJ, Kazi A, et al. Anti-angiogenic and anti-tumor properties of proteasome inhibitors. Curr Cancer Drug Targets. 2005;5:529–541
  4. Tanahashi N, Tsurumi C, Tamura T, Tanaka K. Molecular structure of 20S and 26S proteasomes. Enzyme Prot. 1993;47:241–251
  5. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071–3076
  6. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617
  7. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethazone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498
  8. Lü S, Wang J, Xu X, et al. Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. Int J Hematol. 2009;89:34–38
  9. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:667–675
  10. Leonard JP, Furman RR, Coleman M. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer. 2006;119:971–979
  11. Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004;15:10
  12. Satou Y, Nosaka K, Koya Y, et al. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia. 2004;18:1357–1363
  13. Nasr R, El-Sabban ME, Karam JA, et al. Efficacy and mechanism of action of the proteasome HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene. 2005;24:419–430
  14. Lü S, Chen Z, Yang J, et al. The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02. Int J Lab Hematol. 2009;Feb 25. Epub ahead of print
  15. Cheriyath V, Jacobs BS, Hussein MA. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors. Drugs R D. 2007;8:1–12
  16. Chauhan D, Li G, Podar K, et al. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004;104:2458–2466
  17. Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003;63:6174–6177
  18. Shringarpure R, Catley L, Bhole D, Anderson KC. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006;134:145–156
  19. Lü S, Yang J, Song X, et al. Point mutation of the PSMB5 gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther. 2008;326:423–431
  20. Lü S, Chen Z, Yang J, et al. Overexpression of the PSMB5 Gene Contributes to Bortezomib Resistance in T Lymphoblastic lymphoma/Leukemia Cells Derived from Jurkat Line. Exp Hematol. 2008;36:1278–1284
  21. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112:2489–2499
  22. Small BC, Murdock CA, Bilodeau-Bourgeois AL, Peterson BC, Waldbieser GC. Stability of reference genes for real-time PCR analyses in channel catfish (Ictalurus punctatus) tissues under varying physiological conditions. Comp Biochem Physiol B Biochem Mol Biol. 2008;151:296–304Epub 2008 Jul.
  23. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem. 2000;46:673–683
  24. Groll M, Berkers CR, Ploegh HL, et al. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006;14:451–456

PII: S0301-472X(09)00128-3

doi: 10.1016/j.exphem.2009.04.001

Experimental Hematology
Volume 37, Issue 7 , Pages 831-837 , July 2009

Article Tools

* Image Usage & Resolution